This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Examples of pills with more oestrogenic activity

Authoring team

Most pills contain 30-35 micrograms of ethinylestradiol (this may be higher in phased pills) whereas lower-strength pills contain 20 micrograms of ethinylestradiol. The newer pills Qlaira and Zoely contain bioidentical rather than synthetic oestrogen.

Examples of higher dose oestrogen pills include:

  • Brevinor - contains 35 micrograms of ethinyl oestradiol and 500 micrograms norethisterone - considered more oestrogenic than many other pills because it has a higher oestrogen component
  • Norimin - as for Brevinor but contains 1mg norethisterone
  • Marvelon - considered more oestrogenic because its progestogen component (150 micrograms desogestrel) has less of a counteractive effect on the actions of the oestrogen (30 micrograms ethinyl oestradiol)
  • Other higher oestrogen pills include Cilest, Cilique, Lizilla and Dianette

Note - Qlaira contains 1-3 mg estradiol valerate and 2 -3 mg dienogest. Zoely contains 2.5 mg nomegestrol acetate and 1.5 mg estradiol (as hemihydrate).


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2025 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.